S&P 500   4,574.60 (+0.00%)
DOW   35,636.75 (-0.34%)
QQQ   381.91 (+0.74%)
AAPL   149.33 (+0.01%)
MSFT   324.14 (+4.52%)
FB   315.27 (-0.17%)
GOOGL   2,949.54 (+5.86%)
TSLA   1,046.22 (+2.73%)
AMZN   3,397.57 (+0.64%)
NVDA   248.05 (+0.36%)
BABA   168.65 (-0.79%)
NIO   39.67 (-1.98%)
CGC   12.97 (-1.52%)
GE   103.93 (-3.27%)
AMD   123.73 (+0.65%)
MU   68.31 (-0.91%)
T   25.14 (-0.91%)
F   15.74 (-1.25%)
ACB   6.91 (-1.71%)
DIS   169.98 (-1.20%)
PFE   42.82 (-1.70%)
BA   206.71 (-1.48%)
AMC   35.25 (-2.22%)
S&P 500   4,574.60 (+0.00%)
DOW   35,636.75 (-0.34%)
QQQ   381.91 (+0.74%)
AAPL   149.33 (+0.01%)
MSFT   324.14 (+4.52%)
FB   315.27 (-0.17%)
GOOGL   2,949.54 (+5.86%)
TSLA   1,046.22 (+2.73%)
AMZN   3,397.57 (+0.64%)
NVDA   248.05 (+0.36%)
BABA   168.65 (-0.79%)
NIO   39.67 (-1.98%)
CGC   12.97 (-1.52%)
GE   103.93 (-3.27%)
AMD   123.73 (+0.65%)
MU   68.31 (-0.91%)
T   25.14 (-0.91%)
F   15.74 (-1.25%)
ACB   6.91 (-1.71%)
DIS   169.98 (-1.20%)
PFE   42.82 (-1.70%)
BA   206.71 (-1.48%)
AMC   35.25 (-2.22%)
S&P 500   4,574.60 (+0.00%)
DOW   35,636.75 (-0.34%)
QQQ   381.91 (+0.74%)
AAPL   149.33 (+0.01%)
MSFT   324.14 (+4.52%)
FB   315.27 (-0.17%)
GOOGL   2,949.54 (+5.86%)
TSLA   1,046.22 (+2.73%)
AMZN   3,397.57 (+0.64%)
NVDA   248.05 (+0.36%)
BABA   168.65 (-0.79%)
NIO   39.67 (-1.98%)
CGC   12.97 (-1.52%)
GE   103.93 (-3.27%)
AMD   123.73 (+0.65%)
MU   68.31 (-0.91%)
T   25.14 (-0.91%)
F   15.74 (-1.25%)
ACB   6.91 (-1.71%)
DIS   169.98 (-1.20%)
PFE   42.82 (-1.70%)
BA   206.71 (-1.48%)
AMC   35.25 (-2.22%)
S&P 500   4,574.60 (+0.00%)
DOW   35,636.75 (-0.34%)
QQQ   381.91 (+0.74%)
AAPL   149.33 (+0.01%)
MSFT   324.14 (+4.52%)
FB   315.27 (-0.17%)
GOOGL   2,949.54 (+5.86%)
TSLA   1,046.22 (+2.73%)
AMZN   3,397.57 (+0.64%)
NVDA   248.05 (+0.36%)
BABA   168.65 (-0.79%)
NIO   39.67 (-1.98%)
CGC   12.97 (-1.52%)
GE   103.93 (-3.27%)
AMD   123.73 (+0.65%)
MU   68.31 (-0.91%)
T   25.14 (-0.91%)
F   15.74 (-1.25%)
ACB   6.91 (-1.71%)
DIS   169.98 (-1.20%)
PFE   42.82 (-1.70%)
BA   206.71 (-1.48%)
AMC   35.25 (-2.22%)
LON:VENN

Venn Life Sciences Share Forecast, Price & News

GBX 6.85
+0.45 (+7.03 %)
(As of 06/27/2019)
Add
Compare
Today's Range
6.70
7
50-Day Range
6.85
6.85
52-Week Range
1.55
7.25
Volume1.03 million shs
Average Volume566,253 shs
Market Capitalization£4.89 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive VENN News and Ratings via Email

Sign-up to receive the latest news and ratings for Venn Life Sciences and its competitors with MarketBeat's FREE daily newsletter.


About Venn Life Sciences

Venn Life Sciences Holdings Plc, a clinical research organization, provides consulting and clinical trial services to pharmaceutical, biotechnology, and medical device companies in the United Kingdom, Ireland, France, the Netherlands, Germany, and Singapore. The company offers drug development planning and strategy services, including clinical feasibility assessment, project management, and in-licensing and technical due diligence; and early drug development services, such as drug candidate selection, CMC, non-clinical/pre-clinical development, clinical pharmacology, pharmacokinetics, and pharmacometrics and PK-PD modelling. It also provides clinical trial services comprising clinical feasibility assessment, project management, clinical and medical monitoring, biometrics, biostatistics, data management and databases integration, ISC/IDMC, RTSM, investigator initiated studies, and resourcing and recruitment. In addition, the company offers regulatory affairs and consulting, quality assurance, and legal services, as well as drug development training and courses. The company has a strategic collaboration with Open Orphan DAC for the clinical research and regulatory consulting for companies developing products under the auspices of the various Orphan Drug frameworks. The company was founded in 2012 and is headquartered in Dublin, Ireland.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Medical Care
Sub-Industry
N/A
Sector
N/A
CIK
N/A
Employees
157
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
GBX 15.60 per share

Profitability

Debt

Price-To-Earnings

Miscellaneous

Market Cap
£4.89 million
Next Earnings Date
N/A
Optionable
Not Optionable

MarketRank

Overall MarketRank

0.97 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.7 5 -4 -3 -2 -1 -












Venn Life Sciences (LON:VENN) Frequently Asked Questions

What stocks does MarketBeat like better than Venn Life Sciences?

Wall Street analysts have given Venn Life Sciences a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Venn Life Sciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are Venn Life Sciences' key executives?

Venn Life Sciences' management team includes the following people:
  • Mr. Anthony Richardson, CEO, Exec. Director & Company Sec. (Age 55)
  • Dr. Christian Bernard Milla, COO & Director (Age 57)

What other stocks do shareholders of Venn Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Venn Life Sciences investors own include Nielsen (NLSN), Bank of Hawaii (BOH), BJ's Wholesale Club (BJ), Biogen (BIIB), Bank of America (BAC), Arrow Electronics (ARW), Art's-Way Manufacturing (ARTW), Arconic (ARNC), ADOMANI (ADOM) and Adobe (ADBE).

What is Venn Life Sciences' stock symbol?

Venn Life Sciences trades on the London Stock Exchange (LON) under the ticker symbol "VENN."

How do I buy shares of Venn Life Sciences?

Shares of VENN and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Venn Life Sciences' stock price today?

One share of VENN stock can currently be purchased for approximately GBX 6.85.

How much money does Venn Life Sciences make?

Venn Life Sciences has a market capitalization of £4.89 million.

How many employees does Venn Life Sciences have?

Venn Life Sciences employs 157 workers across the globe.

What is Venn Life Sciences' official website?

The official website for Venn Life Sciences is www.vennlifesciences.com.

Where are Venn Life Sciences' headquarters?

Venn Life Sciences is headquartered at 1 Berkeley Street, LONDON, W1J 8DJ, United Kingdom.

How can I contact Venn Life Sciences?

Venn Life Sciences' mailing address is 1 Berkeley Street, LONDON, W1J 8DJ, United Kingdom. The company can be reached via phone at +44-28-90737900.


This page was last updated on 10/27/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.